



(51) International Patent Classification:

C07C 233/11 (2006.01) A61P 25/00 (2006.01)

C07D 213/56 (2006.01) A61K 31/165 (2006.01)

C07D 231/12 (2006.01)

(21) International Application Number:

PCT/US2023/025936

(22) International Filing Date:

22 June 2023 (22.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2209195.3

22 June 2022 (22.06.2022)

GB

(71) Applicant: ACADIA PHARMACEUTICALS INC.

[US/US]; 12830 El Camino Real, Suite 400, San Diego, California 92130 (US).

(72) Inventors: QUIBELL, Martin; Pandeia Therapeutics

Limited, c/o The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge Cambridgeshire CB22 3FH (GB). SCHULZ-UTERMOEHL, Tim; Pandeia Therapeutics Limited, c/o The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge Cambridgeshire CB22 3FH (GB). MURRAY, Fraser; Pandeia Therapeutics Limited, c/o The Cambridge Partnership Limited, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge Cambridgeshire CB22 3FH (GB).

(74) Agent: CARROLL, William A. et al.; 790 N. Water Street,

Suite 2500, Milwaukee, Wisconsin 53202 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

(57) Abstract: Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

